NCT01152398View on ClinicalTrials.gov

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Breast Cancer

Interventions

BIOLOGICAL

MVA-BN-HER2

experimental vaccine, subcutaneous injection q4weeks x6

Trial Locations (1)

94704

Alta Bates Comprehensive Cancer Center, Berkeley

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT01152398 - A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy | Biotech Hunter | Biotech Hunter